Pfizer’s oral CDK4 inhibitor shows promise in second-line breast cancer

Pfizer’s CDK4 inhibitor, atirmociclib, is already being investigated in a Phase III trial as a first-line therapy.
Business Wire

Parabilis Medicines to Present Trial-in-Progress Poster on Phase 1/2 Study of FOG-001, a β-catenin TCF4 Inhibitor, at ASCO Gastrointestinal Cancers Symposium

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Parabilis Medicines (formerly Fog Pharmaceuticals), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for people living with ...
Nature

Cooperative inhibition in cytochrome P450 between a substrate and an apparent non-competitive inhibitor

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
News Medical

Insights into kinase inhibitors' therapeutic potential in neurodegenerative diseases

Few effective treatments exist to treat neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). 1 Existing treatments focus on ...